The Juvenile Myelomonocytic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures JMML-specific pre-HCT data such as: the recipient’s hematologic and cytogenetic findings at the time of diagnosis and prior to the start of the preparative regimen, pre-HCT treatments administered, and disease status prior to the start of the preparative regimen.
This form must be complete for all recipients randomized to the Comprehensive Report Form (CRF) track whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as Myelodysplastic (MDS)/myeloproliferative (MPN) diseases and the subtype is reported as Juvenile Myelomonocytic Leukemia (JMML/JCML); also for all recipients with AML whose disease transformed from JMML.
Subsequent Transplant
If this is a report of a second or subsequent transplant for the same disease subtype and this baseline disease insert was not completed for the previous transplant (e.g., patient was on TED track for the prior HCT, prior HCT was autologous with no consent, etc.), begin at question 1.
If this is a report of a second or subsequent transplant for a different disease (e.g., patient was previously transplanted for a disease other than Juvenile Myelomonocytic Leukemia), begin at question 1.
If this is a report of a second or subsequent transplant for the same disease and this baseline disease insert has previously been completed, check the indicator box and continue with question 63.
Q1-6: Clinical Features at Diagnosis
Q7-48: Laboratory Values at Diagnosis
Q49-62: Pre-HCT Therapy
Q63-64: Transformation
Q65-91: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen
Q92-93: Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen
Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.
| Date | Manual Section | Add/Remove/Modify | Description |
|---|---|---|---|
| 4/21/2023 | 2015: JMML Pre-HCT | Modify | Clarified the instructions for the labs at diagnosis should reflect the labs closest to the date of diagnosis in Q7. |
| 10/7/2020 | 2015: JMML Pre-HCT | Add | Clarification added to question 49 to explain how to report lines of therapy for subsequent infusions: Lines of Therapy and Subsequent Infusions If this is a subsequent infusion and a 2015 was completed for the previous infusion, lines of therapy do not need to be reported in duplication on the subsequent 2015. Please report from post previous infusion to time of preparative regimen / infusion for the current infusion. If a 2015 was not previously completed, all lines of therapy from diagnosis to the current preparative regimen / infusion must be completed. |
| 2/24/17 | Comprehensive Disease-Specific Manuals | Modify | Updated explanations of triggers for disease inserts to refer to the primary disease reported on the Pre-TED Disease Classification Form (Form 2402) instead of the Pre-TED Form (Form 2400) |
| 6/26/15 | 2015: JMML Pre-HCT | Modify | Modified text of Questions 63 to include the following concept: Progression to AML: ≥ 20% blasts in the blood or bone marrow |
Need more help with this?
Don’t hesitate to contact us here.